Dental Cleaning in Patients on Brukinsa (Zanubrutinib)
Patients taking Brukinsa can safely undergo routine dental cleaning without holding the medication, but the dentist must be informed of the bleeding risk and appropriate precautions should be taken.
Key Recommendation
The FDA label for Brukinsa explicitly addresses dental procedures: "Consider the benefit-risk of withholding BRUKINSA for 3-7 days before and after surgery depending upon the type of surgery and the risk of bleeding" 1. However, this guidance specifically refers to surgical procedures, not routine dental cleanings.
For minor dental procedures (which includes routine cleanings), the most recent perioperative antithrombotic management guidelines recommend continuing antiplatelet therapy rather than stopping it 2. While Brukinsa is not technically an antiplatelet agent, it carries similar bleeding risks and the same principles apply.
Clinical Approach
For Routine Dental Cleaning (Non-Surgical)
- Continue Brukinsa without interruption
- Inform the dentist about the medication and bleeding risk
- Use gentle cleaning techniques with soft instruments 3
- Apply local hemostatic measures if minor bleeding occurs
For Surgical Dental Procedures
If the cleaning involves surgical elements (deep scaling with tissue manipulation, extractions):
- Consider holding Brukinsa for 3-7 days before and after the procedure 1
- Coordinate with the prescribing oncologist/hematologist
- Balance bleeding risk against thrombotic complications from drug interruption
Rationale and Evidence
Bleeding Risk with Brukinsa: The FDA label reports that bleeding of any grade occurred in 32% of patients, with Grade 3 or higher hemorrhage in 3.8% 1. Fatal hemorrhages occurred in 0.2% of patients. This establishes that bleeding is a real concern but is manageable in most cases.
Dental Procedure Guidelines: The 2022 CHEST guidelines for perioperative antithrombotic management specifically address minor dental procedures, recommending continuation of antiplatelet drugs rather than interruption 2. The evidence shows no significant increase in major bleeding with continuation of antiplatelet therapy during routine dental cleanings.
Infection Risk Considerations: Brukinsa carries significant infection risks (Grade 3+ infections in 26% of patients) 1. Maintaining good oral hygiene through regular dental cleanings is actually protective against infections. The ESMO guidelines emphasize that dental care should continue throughout cancer therapy, with patients instructed to "have your dental team eliminate sources of trauma" 3.
Practical Management
Before the Appointment
- Check recent complete blood count - particularly platelet count and neutrophil count
- If platelets <50,000/mm³ or neutrophils <500/mm³: defer elective cleaning until counts recover 1
- Inform the dentist about Brukinsa use and bleeding precautions needed
During the Cleaning
- Use ultra-soft bristle instruments 4
- Avoid aggressive subgingival scaling if not necessary
- Have local hemostatic agents available (tranexamic acid rinse, gelatin sponges)
- Monitor for excessive bleeding during the procedure
After the Cleaning
- Instruct patient to use gentle oral care with soft toothbrush 3
- Rinse with bland saline/bicarbonate solution (not alcohol-based mouthwash) 4
- Watch for delayed bleeding and report immediately if persistent
- Avoid NSAIDs for post-procedure discomfort (use acetaminophen instead)
Critical Caveats
Do NOT routinely discontinue Brukinsa for simple cleanings. The oncologic indication for Brukinsa (CLL/SLL, MCL, WM, MZL, FL) means these patients have active hematologic malignancies. Interrupting therapy unnecessarily risks disease progression, which poses far greater morbidity and mortality risk than minor bleeding from a dental cleaning.
Coordinate with the oncology team if there is any uncertainty about the patient's current disease status, blood counts, or appropriateness of holding the medication. The decision to hold Brukinsa should never be made unilaterally by the dentist or primary care provider.
Distinguish between cleaning and surgery. A routine prophylaxis/cleaning is fundamentally different from extractions, implant placement, or periodontal surgery. The latter procedures warrant serious consideration of holding Brukinsa for 3-7 days as per FDA guidance 1.